Chrnb2 Protein — Nicotinic Receptor Beta 2 Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Field | Value |
|-------|-------|
| **Protein Name** | CHRNB2 / nAChR β2 |
| **Gene** | CHRNB2 |
| **UniProt ID** | P17787 |
| **PDB ID** | 5KXI, 6CNG |
| **Molecular Weight** | ~57 kDa |
| **Subcellular Localization** | Plasma membrane |
| **Protein Family** | Cys-loop receptor family |
| **Structure** | Pentameric ligand-gated ion channel |
CHRNB2 encodes the beta-2 subunit of the nicotinic acetylcholine receptor (nAChR). This subunit is a critical component of neuronal nicotinic receptors, particularly the α4β2* receptor, which is the most abundant nicotinic receptor in the brain. The receptor is a pentameric ligand-gated ion channel that mediates fast synaptic transmission at cholinergic synapses.
The nAChR is a pentameric assembly:
- Five subunits surround a central ion channel
- Each subunit contains an extracellular N-terminus, four transmembrane domains (M1-M4), and an extracellular C-terminus
- The ligand-binding site is at the interface between subunits
| Receptor |
Stoichiometry |
Brain Expression |
| α4β2 |
α4:β2 = 2:3 |
Highest in brain |
| α3β2 |
α3:β2 |
Autonomic ganglia |
| α2β2 |
α2:β2 |
Limited brain regions |
- Fast excitatory neurotransmission
- Modulation of neurotransmitter release
- Regulation of neuronal excitability
- Cognitive processes (attention, learning, memory)
- Reward and addiction mechanisms
| Property |
Value |
| Conductance |
30-40 pS |
| Ion selectivity |
Permeable to Na+, Ca2+, K+ |
| Desensitization |
Slow (seconds) |
| Activation |
Acetylcholine, nicotine |
Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
- Gain-of-function mutations identified
- Increased channel activity leads to hyperexcitability
- First CHRNB2 mutation: V287M
- α4β2 receptor density decreases in AD cortex
- Amyloid-beta peptides bind to nAChRs
- Cholinergic hypothesis relates to receptor loss
- AChE inhibitors work partially through these receptors
- Loss of nAChR expression in substantia nigra
- Contributes to motor and non-motor symptoms
- Nicotine may provide neuroprotection
- β2-containing receptors mediate nicotine reward
- CHRNB2 knockout mice: no nicotine self-administration
- Genetic variants affect smoking behavior
| Drug |
Mechanism |
Indication |
| Nicotine |
Partial agonist |
Smoking cessation |
| Varenicline |
Partial agonist |
Nicotine dependence |
| Cytisine |
Partial agonist |
Smoking cessation |
| Donepezil |
AChE inhibitor |
AD |
| Rivastigmine |
AChE inhibitor |
AD/DLB |
- α4β2-selective agonists
- Positive allosteric modulators
- Subunit-selective compounds
- PMID:11834136 - CHRNB2 mutations cause ADNFLE (2002)
- PMID:14675536 - β2 in nicotine addiction (2003)
- PMID:15671259 - nAChRs in AD (2005)
- PMID:25481418 - α4β2 structure (2015)
- PMID:33439810 - nAChR cryo-EM structure (2021)
The study of Chrnb2 Protein — Nicotinic Receptor Beta 2 Subunit has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:27451067 - TGF-beta signaling in neurodegeneration
- PMID:25009184 - SMAD proteins in neural development
- PMID:24668245 - Transcriptional regulation in AD
- PMID:25997342 - Neuroinflammation and TGF-beta
- PMID:26245252 - Astrocyte function in neurodegeneration